Arcellx Soars 78% on Gilead's $7.8 Billion Buyout Offer

Shares of Arcellx (ACLX) exploded nearly 78% in a single day after Gilead Sciences (GILD) announced a definitive agreement to acquire the company for approximately $7.8 billion. The offer of $115 per share in cash represents a substantial 68% premium to Arcellx's recent trading price, catapulting the stock to a new all-time high.

The deal also includes a potential sweetener: a contingent value right (CVR) worth an additional $5 per share. This bonus payment is triggered if Arcellx's lead drug, anito-cel, achieves cumulative global sales of at least $6 billion by the end of 2029. Both companies' boards have approved the transaction, which is expected to close in the second quarter of 2026.

This acquisition formalizes and expands an existing collaboration between Gilead's Kite Pharma unit and Arcellx that began in 2022. The partnership was centered on developing anito-cel, a CAR-T cell therapy designed to treat multiple myeloma. By buying Arcellx outright, Gilead gains complete ownership and control over the drug's future.

The transaction effectively locks in a significant return for Arcellx shareholders at the $115 price point. Analyst reaction was swift, with Wells Fargo downgrading the stock to Equal-Weight with a $115 target, signaling that most of the immediate gains from the deal have likely been realized.

This acquisition is a major strategic move for Gilead, allowing it to fully consolidate the potential upside of a promising late-stage cancer therapy. CAR-T therapy is a cutting-edge treatment that involves reprogramming a patient's own immune cells to fight cancer, and it has shown remarkable success in blood cancers like multiple myeloma.

For Gilead, the deal eliminates the complexities of the previous profit-sharing arrangement with Arcellx. Instead of sharing revenues and paying royalties, Gilead will now capture 100% of the profits if anito-cel is approved and becomes a commercial success. The company already owned about 11.5% of Arcellx, showing its deep belief in the therapy's potential.

The key driver of the deal's value is anito-cel itself. The FDA has accepted its application for approval, with a decision expected by the end of 2026. If approved, it would enter a competitive but lucrative market for multiple myeloma treatments, posing a challenge to existing therapies from companies like Johnson & Johnson.

Gilead's management has projected that the acquisition will begin to boost the company's earnings per share starting in 2028. This makes the $7.8 billion price tag a long-term bet on anito-cel becoming a blockbuster drug, a bet that Gilead is now making with full conviction.